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Background: MicroRNAs are a population of short non-coding RNAs with widespread negative regulatory impact
on mRNA translation. Unrestricted somatic stem cells (USSC) are a rare population in human cord blood that can
be induced into cells representative of all three germinal layers. Here we analyzed the functional impact of miRNAs
on the osteogenic differentiation in USSC.
Results: Gene expression profiling identified 20 microRNAs that were consistently upregulated during osteogenic
differentiation of two different USSC cell lines (SA5/73 and SA8/25). Bioinformatic target gene prediction indicated
that among these microRNAs, miR-10a, -22, -26a, -26b, and -29b recognize transcripts that encode a set of proteins
inhibiting osteogenesis. We subsequently verified osteo-inhibitory CDK6, CTNNBIP1, HDAC4, and TOB1 and osteo-
promoting SMAD1 as targets of these microRNAs. In Western blot analyses demonstrated that endogenous levels
of CDK6 and HDAC4 were downregulated during osteogenic differentiation of USSC and reduced following ectopic
expression of miR-26a/b and miR-29b. In contrast, endogenous expression of SMAD1, targeted by miR-26a/b, was
unaltered during osteogenic differentiation of USSC or following ectopic expression of miR-26a/b. Functional
overexpression analyses using microRNA mimics revealed that miR-26a/b, as well as miR-29b strongly accelerated
osteogenic differentiation of USSC as assessed by Alizarin-Red staining and calcium-release assays.
Conclusions: miR-26a/b and miR-29b are upregulated during osteogenic differentiation of USSC and share target
genes inhibiting osteogenesis. Furthermore, these microRNAs accelerate osteogenic differentiation, likely mediated
by osteo-inhibitory proteins such as CDK6 and HDAC4.
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microRNA (miRNA)-mediated translational repression is
an important regulatory mechanism in multiple cellular
processes. miRNAs are a subpopulation of small RNAs,
averaging 22 nucleotides in length, which inhibit transla-
tion through sequence-specific binding to target sites
within the 30-UTRs of mRNAs. Following transcription,
miRNAs are processed in a two-step mechanism involving
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distribution, and reproduction in any mediumintegrated into the RNA-induced silencing complex [3,4],
thereby unfolding their regulatory potential to regulate
mRNAs [5-7]. Exhibiting stage- and tissue-specific expres-
sion patterns during development [8,9], miRNAs not only
function as key regulatory molecules in multiple cellular
processes including apoptosis [10,11], cancer [12], pro-
liferation [13], development [14], and differentiation [15]
but also control stemness and pluripotency of embryonic
stem cells e.g. by repressing pluripotency factors OCT4,
SOX2 and KLF4 [16].
Osteogenesis is a highly coordinated process involving
transcription factors, such as RUNX2 and OSTERIX
[17,18], BMP2, and other factors, that drive committedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in [19-21]). Osteogenesis is promoted through several
signalling pathways, including WNT/ß-catenin, BMP,
JAK/STAT, and MAPK [22-27]. Several miRNAs modu-
late osteogenic differentiation: miR-125b negatively regu-
lates osteoblastic differentiation through targeting VDR,
ErbB2, and Osterix [28,29]; miR-133 (targeting RUNX2)
and miR-135 (recognizing SMAD5) inhibit differentiation
of mouse osteoprogenitors [30]; miR-26a and miR-29b
facilitate osteogenic differentiation of human adipose
tissue-derived stem cells (hADSCs), and positively modu-
late mouse osteoblast differentiation [31,32]. Multiple
other miRNAs, including miR-9, -17, -27, -30, -96, -106, -
138, -181, -182, -320, and −326, have been linked to osteo-
genesis [30].
Unrestricted somatic stem cells (USSC) are a rare
CD45-negative population in human cord blood [33].
These cells can be discriminated from CB-MSC and BM-
MSC by their HOX expression pattern which resembles
that of H9 embryonic stem cells [34]. Adherently-growing
in vitro USSC can be induced to cells representative of all
three germinal layers on a clonal level [35] and have been
successfully reprogrammed to a pluripotent ES-like state
[36]. Undergoing miRNA-supported cell cycle arrest,
USSC can be differentiated into cells of neural lineage with
miRNAs acting as network-like regulators [37-39]. USSC
also differentiate into functional hepatic-like cells [40,41]
as well as along osteogenic and chondrogenic lineages
[33]. Upon induction with dexamethasone, ascorbic acid,
and ß-glycerol phosphate (DAG), USSC differentiate into
osteoblasts as evidenced by calcium phosphate deposition,
bone-specific ALP-activity, increase in Ca2+-release, and
expression of the osteogenic marker proteins osteocalcin,
osteopontin, bone sialo-protein, and collagen type I [33].
Bony reconstitution was observed following implantation
of USSC into nude rat femurs [33]. Beside their differenti-
ation potential, USSC also fulfil regenerative functions in
acute spinal cord trauma [42].
Here we analyzed the impact of miRNAs on osteogenic
differentiation of USSC. We identified a set of miRNAs
upregulated upon induction of osteogenesis, co-ordinately
regulating a distinct set of genes known to inhibit os-
teogenesis. Among these inhibitors, CDK6, CTNNBIP1,
HDAC4, TGFB3, and TOB1 were experimentally identi-
fied as targets of miR-26a, miR-26b, and miR-29b. These
miRNAs were functionally identified as accelerators of
osteogenic differentiation of USSC.
Results
Differential miRNA expression during osteogenic
differentiation of USSC
To assess the impact of miRNAs on osteogenic differenti-
ation of USSC we studied two USSC lines (USSC SA5/73
and USSC SA8/25) that were induced to osteogenicdifferentiation using DAG as described [33]. As strong cal-
cification of USSC during osteogenic differentiation
impacts RNA isolation, we restricted our analyses to day 7
of differentiation. miRNA expression profiles of native and
day 7 osteo-differentiated USSC were analyzed using the
RT-PCR-based TaqMan Assay (Pool A) covering 377
miRNAs [43]. In SA5/73, 220 miRNAs were expressed
and 124 miRNAs were upregulated by a factor ≧ 2 in
differentiated cells. In SA8/25, 225 miRNAs were ex-
pressed and 196 miRNAs were upregulated during osteo-
genic differentiation. Interestingly, only 30 miRNAs were
commonly upregulated in both USSC lines. In follow-up
analyses we focused on 20 of these microRNAs (Figure 1),
which were not only upregulated by a factor ≧ 2 but also
present at high expression levels (< Ct 26) in differentiated
USSC. We omitted those upregulated miRNAs that were
weakly expressed in differentiated USSC due to their
expected minor biological impact. Among the most prom-
inently expressed miRNAs were miR-10a, miR-152, miR-
22, miR-26a/b, miR-29b, miR-30b/c, miR-345, and miR-
532-5p. Complete miRNA expression data from USSC
SA5/73 and SA8/25 osteogenic differentiation experi-
ments are presented in Additional file 1.
Bioinformatic target gene predictions
To investigate the biological impact of our selected set of
20 miRNAs, we computationally identified miRNA targets
using the DIANA miRGen target gene prediction software
[44], which combines the prediction results of several
web-based algorithms (TargetScan, PicTar-4, PicTar-5, mi-
Randa, DIANA microT). This approach resulted in an ex-
tensive list of putative targets (>104 genes), many of which
were recognized by more than one of our 20 miRNAs. As
our study is focused on miRNAs that are upregulated
during osteogenic differentiation, we reasoned that their
biological impact should be posttranscriptional down-
regulation of proteins inhibiting osteogenic differentiation.
We thus filtered our list of putative targets using the Gene
Ontology (GO) terms function implemented in the DAVID
database, applying search terms like “bone” and “osteo”.
Table 1 presents an overview of 21 proteins inhibiting
osteogenic differentiation that are putatively recognized
by our set of 20 miRNAs. Consistent with the view that
miRNAs regulate networks [38], Table 1 demonstrates tar-
get gene redundancy: certain proteins were predicted to be
targeted by more than one miRNA and other miRNAs (e.g.
miR-29b) putatively regulate up to 11 proteins (Table 1).
Computational predictions indicated that the BMP-2
antagonist CDK6 [45-47] was recognized by six miRNAs
(miRs-101, -137, -22, -26a, -26b, and -29b); CTNNBIP1
(also termed ICAT), an inhibitor of ß-catenin mediated
transcription [48], was likely regulated by five miRNAs
(miRs-10a, -192, -26a, -26b, and -29b); and Runx2 co-
repressor HDAC4 [49] was a putative target of four
Figure 1 Differential miRNA expression during DAG-mediated
osteogenic differentiation of USSC lines SA5/73 and SA8/25.
The heat map shows common upregulation of 20 miRNAs in both
cell lines as measured by qRT-PCR, together with the fold changes
(2–ddCt) of miRNA expression in DAG-induced USSC at day 7 of
osteogenic differentiation compared to the native cells. MicroRNAs
highlighted in red were selected for further studies. Full miRNA
expression data are presented in Additional file 1.
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tative osteogenesis-inhibiting target proteins included
DUSP2 [50], TOB1 [51], TGFB3 [52,53], and SMAD6
[54] (see Table 1 for target predictions). Interestingly,
miR-26a and miR-26b were also predicted to regulate
SMAD1, a positive regulator of osteogenic differenti-
ation [55].
The most redundant miRNA-target network involved
miR-26a/b and miR-29b and, to a lesser extent, miR-22,
miR-10a, and miR-137 (Table 1); subsequent analyses fo-
cused on these six miRNAs. To avoid errors in measuring
the expression of highly homologous miR-26a and -26b,
we verified our TaqMan miRNA expression data from
USSC SA5/73 and SA8/25 (Figure 1) in native USSC linesSA5/73, SA8/25, SA8/77 and SA4/101 and in (day 7) osteo
differentiated SA8/77 and SA4/101, using an established
small RNA sequencing method [56,57]. miR-26a and miR-
26b expression was confirmed in all native USSC lines and
both miRNAs were upregulated in differentiated SA8/77
and SA4/101 lines (Additional file 1).
Experimental validation of predicted miRNA targets
Next, we experimentally verified miRNA regulation of
selected targets (Table 1) using an established target valid-
ation assay [38,39]. Among these putative targets, CDK6,
CTNNBIPI, TOB1, and HDAC4 contained the most
predicted miRNA binding sites, whereas DUSP2, TGFB3,
and SMAD6 each contained a solitary putative miR-29b
target site. PCR amplification products representing the
30-UTR of target genes were cloned at the 30-end of the
firefly-ORF of dual luciferase (firefly and renilla) vector
pmirGLO. Based on the patterns of predicted miRNA bind-
ing sites on individual 30-UTRs (see Additional file 2 for
details), we devised the following cloning strategy for target
validation: CDK6 30-UTR (10235 bp) was cloned as two
subfragments ranging from bases 147–4275 (CDK6-1) and
5825–9997 (CDK6-2); CTNNBIP1 (2442 bp) and TGFB3
(1088 bp) 30-UTRs were covered by 1094bp and 277 bp
fragments respectively. The HDAC4 30-UTR (4933 bp) was
represented by a 964 bp PCR-fragment (HDAC4-1) and
two additional 65 bp and 57 bp double-stranded oligo-
nucleotides (HDAC4-O1, -O2) covering single miRNA
binding sites. Using oligonucleotides instead of longer 30-
UTR fragments is well described in the literature (e.g. see
[58]). TOB1, DUSP2, SMAD1, and SMAD6 30UTRs
were respectively represented by double-stranded oligo-
nucleotides of 65 bp, 58 bp, 37 bp, and 116 bp. In
addition, an oligonucleotide pair with mutated seed
sequences was used for TOB1.
Pairs of pmirGLO and pmirGLO/30-UTR were cotrans-
fected into HEK293T cells with the appropriate miRNA-
mimic (Dharmacon) to assess the activity of a specific
miRNA on a given 30-UTR. Figures 2A and 2B depict
renilla-normalized firefly activities measured from co-
transfections of each mimic miR-10a, -22, -26a, -26b, -29b
, and −137 with pmirGLO compared to co-transfections
of these mimics with pmirGLO/CDK6-1-30-UTR
(Figure 2A) and pmirGLO/CDK6-2-30-UTR (Figure 2B)
respectively. The percentage reduction of relative firefly
activities in pmirGLO/30-UTR + mimic compared to ac-
tivities of pmirGLO + mimic transfections correlate with
miRNA activity on the given 30-UTR. Here we identified
strong interactions between CDK6-2 and miR-26a and
miR-26b and moderate interactions with miR-29b. miR-22
and miR-29b interacted with fragment CDK6-1.
Figure 3 summarizes the results of experimental
validations from all 22 predicted miRNA-target inter-
actions: CDK6 was targeted by miR-22, miR-26a, miR-26b,




Total 101 10a 137 152 192 22 26a 26b 29b 30b 30c 324- 337 345 483 501 532 590 598 660
3p
CDK6 6 x x x x x x
CTNNBIP1 5 x x x x x*
AHSG 4 x x x x
HDAC4 4 x x x* x
CHRD 3 x x x
COL1A1 3 x x x
SOX2 3 x x x
COL4A2 2 x x*
DUSP2 2 x* x
HIPK2 2 x x
NOG 2 x x
SKI 2 x x
SMAD7 2 x x
SOSTDC1 2 x x
STATH 2 x x
TGFB3 2 x x*





Bioinformatic target predictions for the subset of 20 miRNAs upregulated in osteogenic differentiation of USSC on osteo-inhibitory proteins: miR-26a, -26b, and -29b
were experimentally assessed for impact on proteins denoted in bold. The second column (“Total”) illustrates the number of miRNAs from the analyzed set that targets
an individual protein. Predictions with an asterix were already validated in the literature.
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miR-29b; SMAD1 and TOB1 were both recognized by
miR-26a and miR-26b; and HDAC4 was targeted by miR-
29b. Validations for DUSP2, SMAD6 and TGFB3 failed to
give strongly positive results, with TGFB3 only weakly
affected by miR-29b. Detailed data for all experimental
validation studies are presented in Additional file 2. In
summary, we identified osteo-inhibitory targets for miR-
10a, miR-22, miR-26a, miR-26b, and miR-29b with the
highest targeting impact resulting from miR-26a, miR-26b,
and miR-29b expression.
Target gene expression analysis and impact of regulating
microRNAs
As the availability of USSC lines SA5/73 and SA8/25 be-
came limited in the course of our study, we focused on
the newer USSC lines 86b and 77 for target gene expres-
sion analyses. Using qPCR, we analyzed transcript expres-
sion of validated targets CDK6, HDAC4, CTNNBIP1,
SMAD1, and TOB1 during osteogenic differentiation of
USSC line 86b at time points day 0 (native cells), and days
7 and 12 post DAG induction. Figure 4 demonstrates thatCDK6, HDAC4, SMAD1, and CTNNBIP1 were all stead-
ily downregulated at days 7 and 12 compared to day 0.
HDAC4 was downregulated at day 7, followed by a slight
increase in expression at day 12, albeit weaker than at day
0. We were unable to identify TOB1 transcripts in USSC.
These results indicate inverse transcriptional regulation of
miRNAs and target-mRNAs inhibiting osteogenic differ-
entiation of USSC.
As miRNAs downregulate their targets on a post-
transcriptional level, we also analyzed HDAC4, CDK6,
and SMAD1 protein expression during osteogenic differ-
entiation (up to day 12) of USSC 86b and in response to
ectopic expression of miR-26a, miR-26b, and miR-29b in
native USSC86b.
As seen in Figure 5A, HDAC4 was weakly expressed in
native USSC 86b and downregulated by a factor 5 in day 9
osteo-differentiated USSC 86b, thereby matching our qPCR
results (Figure 4). The HDAC4 protein level was also
reduced following transfection with miR-29b (Figure 5B).
CDK6 behaved differently on the protein level; this pro-
tein was initially upregulated at day 7 of osteogenic differ-
entiation in USSC 86b, and slightly downregulated at day
Figure 2 Experimental validation of target gene predictions. Experimental validation of putative target sites on 4128bp (A) and 4169bp
(B) fragments of the 10235nt 30-UTR of CDK6 (CDK6-1 and CDK6-2, shown as blue bars with indicated putative miRNA binding sites) for miRNAs
miR-22, -26a, -26b, -29b, and -137 in HEK293T-Cells. To assess the influence of endogenous miRNAs, empty firefly/renilla dual reporter vector
pmirGLO and pmirGLO/CDK6-30-UTRs were each transfected into HEK293T-cells. Normalized firefly-activities were compared to those of pairwise
co-transfections of these vectors with the miRNA mimic of interest (including an unspecific siRNA negative control) to test for unspecific effects
of the given miRNA-mimic on firefly/renilla per se and for validation of the particular target prediction. Dark grey columns show normalized firefly
activities from pmirGLO (co)-transfections, light grey columns those from pmirGLO/CDK6-30-UTRs (co)-transfections. Percent reductions of firefly
activities of pmirGLO/CDK6-30-UTRs compared to pmirGLO are given as well as their statistical significancies (at least two biological replicates with
four technical replicates each, Student’s t-test, unpaired, ** p ≤ 0.01, ***: p ≤ 0.001). Summarizing results from both CDK6-30-UTR fragments,
significant regulatory miRNA effects were seen for miR-22, miR-26a, miR-26b, and miR-29b, whereas miR-137 had no significant effect.
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(Figure 5C). To further examine this unexpected result,
we tested an additional USSC line (USSC 77), which
yielded the same dynamic CDK6 expression pattern
(Figure 5C). Upon independent transfection with (i) an
equimolar mixture of miR-26a and miR-26b mimics (both
miRNAs share their seed sequence and differ in only two
nucleotides) and (ii) with miR-29b mimics, CDK6 protein
abundance was reduced compared to native and negativecontrol cells 48h after transfection (Figure 5D). As with
HDAC4, our results confirm that miR-26a, miR-26b, and
miR-29b target CDK6.
Interestingly, SMAD1 expression remained unchanged
at day 9 post DAG induction compared to native USSC
86b (Figure 5E) and was not affected by transfection
with miR-26a and miR-26b mimics (Figure 5F). We were
unable to detect the weakly transcribed CTNNBIP1 with
any of several established antibodies (data not shown).
Figure 3 Summary of miRNA-target gene validations. In
HEK293T-cells we tested the effects of a total of six miRNA-mimics
(miR-10a, -22, -26a, 26b, 29b, and -137) on the 30-UTRs of 8 predicted
proteins (CDK6, CTNNBIP1, DUSP2, HDAC4, SMAD1, SMAD6, TGFB3,
and TOB1) related to osteogenic differentiation and/or function.
Percent reductions of normalized firefly-activities from pmirGLO/30-
UTR/miRNA-mimic co-transfections compared to pmirGLO/miRNA-
mimic co-transfections are given in the colored squares. Red
squares: lacking or non-significant miRNA effects, orange: weak but
significant (p ≤0,05) miRNA effects, light green: moderate microRNA
effects, dark green: strong microRNA effects. Among 22 individual
miRNA-30-UTR interactions analyzed, 10 were counted as positive
(light and dark green squares). *: predictions already validated in
[32], **: predictions already validated in [31]. These were analyzed
again here for reasons of comparability to our other validations.
Detailed data from all experimental validations are listed in
Additional file 2.
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osteogenic differentiation of USSC
Our experimental target validations indicate that miR-
26a, miR-26b, and miR-29b likely have the strongest im-
pact on osteogenic differentiation of USSC by reducing
osteo-inhibitory CDK6 and HDAC4 proteins. We thus
tested whether overexpression of miR-26a/b and miR-
29b using miRNA mimics influences DAG-induced
osteogenic differentiation. USSC SA5/73 and USSC 86b
were each transfected with (i) a small unspecific negative
control RNA, (ii) an equimolar batch of miR-26a and
miR-26b, (iii) miR-29b, and (iv) an equimolar batch of
miR-26a, miR-26b, and miR-29b mimics (SA5/73 only),
each followed by DAG induction. Osteogenic differenti-
ation was assessed by alizarin-red staining and calcium
release at day 7 (both USSC lines).As seen in Figures 6A and 6B, both USSC lines started
to differentiate at day 7 post DAG induction. Transfection
of negative control RNA did not substantially influence
alizarin-red staining in both USSC SA5/73 (Figure 6A)
and USSC 86b (Figure 6B). In contrast, miR-26a/b-mimic
transfected cells of both USSC lines showed significantly
increased staining (Figures 6A and 6B). Transfection with
miR-29b-mimic also resulted in accelerated osteogenic
differentiation of both lines (Figures 6A and 6B). Trans-
fection of USSC SA5/73 with miR-26a/miR-26b/miR-29b
mimics further increased differentiation (Figure 6A).
The finding that miR-26a, miR-26b, and miR-29b
accelerated osteogenic differentiation of USSC was further
supported by calcium release assays performed in DAG-
induced USSC SA5/73 and 86b at days 0 and 7 of osteo-
genic differentiation. As seen in Figures 7A and 7B, calcium
release increased upon transfection with miR-26a/b and
miR-29b as compared to negative-control transfected and
untransfected USSC SA5/73 (Figure 7A) and USSC 86b
(Figure 7B). Transfection of SA5/73 with the miR-26a/miR-
26b/miR-29b batch showed even higher calcium release,
compared to miR-26a/miR-26b and miR-29b transfections
alone (Figure 7A).
Discussion
USSC are primary cells from human cord blood and are
available in limited amounts from different patient
sources. In general, USSC cell lines, such as SA5/73,
SA8/25, 86b, and 77, are capable of comparable osteo-
genic differentiation as assessed by alizarin-red staining
(data not shown). During osteogenic differentiation, only
30 miRNAs were commonly upregulated in two USSC
lines (SA5/73 and SA8/25), although 124 and 196
miRNAs were respectively upregulated in each cell line.
However, as expected for target-redundant miRNA
networks, evaluation of commonly upregulated miRNAs
revealed multiple bioinformatically osteo-inhibitory tar-
get genes.
miRNA expression profiling followed by target valid-
ation indicated that miR-26a, miR-26b, and miR-29b had
the highest impact on osteogenic differentiation in our
USSC lines. In the mouse osteoblast model, miR-29b is a
positive regulator of osteogenic differentiation, able to in-
crease differentiation on ectopic expression, with HDAC4,
TGFB3, ACVR2A, CTNNBIP1 and DUSP2 as validated
targets [32]. Here we show a comparable function for
miR-29b in osteogenic differentiation of human somatic
stem cells confirming human CTNNBIP1 and HDAC4 as
miR-29b targets in our HEK293T-cell based validation
assay. CTNNBIP1 was also regulated by miR-10a and
CDK6 [45] was targeted by miR-22, miR-26a, miR-26b
and miR-29b.
miR-26a modulates late osteogenic differentiation of
hADSC through SMAD1 targeting [31] and we showed
Figure 4 qPCR analysis of expression profiles of CDK6, HDAC4, SMAD1, and CTTNBIP1 during osteogenic differentiation of USSC 86b
at days 0 (native), 7, and 12. ß-actin normalized dCt values as means from 4 replicates are shown, together with standard deviation and
statistical significancies (Student’s t-test, unpaired, *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001). Increased dCt values correspond to downregulation of
transcripts during osteogenic differentiation and fold changes (2–ddCt) in expression between native and differentiated cells are given for
each transcript.
Trompeter et al. BMC Genomics 2013, 14:111 Page 7 of 13
http://www.biomedcentral.com/1471-2164/14/111that both, miR-26a and miR-26b regulate SMAD1, this
protein is known as a positive mediator of osteogenic dif-
ferentiation [59]. We also identified the osteo-inhibitory
BMP/SMAD regulator TOB1 [51] as a target of miR-26a
and miR-26b. Substantial homology between these two
miRNAs (identical seed sequences) is reflected in their
similar behavior in our target validation assays. To clarify
the contradictory roles of osteo-promoting SMAD1 and
osteo-inhibitory CDK6 and TOB1 as parallel targets of
miR-26a and miR-26b, we directly analyzed target protein
abundance by quantitative Western blotting (i) during
osteogenic differentiation of USSC and (ii) in response to
transfection of USSC with miRNA mimics.
Despite targeting of the SMAD1 30-UTR by miR-26a
and miR-26b in our luciferase assay (Figure 3), SMAD1
protein abundance remained unaltered upon transfection
with miR-26a/b mimics (Figure 5F). This finding indicates
either a long intracellular half-life for SMAD1 in USSC,
unaltered by miRNA transfection in the experimental
timeframe, or secondary regulatory mechanisms such as
increased transcription that keep SMAD1 levels constant.
Accordingly, SMAD1 protein levels also remained con-
stant at day 9 in osteo-differentiated USSC 86b (Figure 5E)
as expected for an osteo-promoting protein. However, our
qPCR data indicate that SMAD1 transcription decreased
steadily from day 0 to day 7 and to day 12 of osteogenic
differentiation (Figure 4), further supporting a long half-
life for SMAD1 protein. Due to strong calcification of
USSC at day 12, we were unable to measure SMAD1 pro-
tein and it remains unclear whether this protein has a long
half-life or is regulated by other unidentified mechanisms.In contrast to osteo-promoting SMAD1, osteo-
inhibitory CDK6 protein expression was indeed reduced
48h post transfection with miR-26a, miR-26b, and miR-
29b mimics. This finding indicates a comparatively strong
regulatory influence of miR-26a/b and miR-29b on CDK6.
However, despite steady transcript downregulation, CDK6
protein expression peaked at day 7 of osteogenic differen-
tiation, before decreasing. As miRNAs act postrans-
criptionally [4,60], the observed decrease of CDK6
abundance at day 12 was likely due to continued up-
regulation of miRNAs targeting osteo-inhibitory factors
beyond day 7, after achieving sufficient levels to alter
CDK6 protein abundance.
The HDAC4 gene product was reduced on both tran-
script (Figure 4) and protein level (Figure 5B) during
osteogenic differentiation. Similarly, the HDAC4 protein
level was reduced upon transfection with miR-29b mimic,
consistent with our target validation assays. It should be
noted that we were unable to detect either TOB1
transcripts or TOB1 and CTNNBIP1 gene products in
USSC (data not shown).
Using alizarin-red staining and calcium release assays,
we clearly demonstrated that miR-26a/b and miR-29b
mimic transfections specifically accelerate osteogenic dif-
ferentiation in both USSC lines tested. This result is
consistent with the observation that miR-29b contributes
to osteogenic differentiation of mouse osteoblasts [32]. It
should be noted that attempts to functionally analyze
miR-10a and miR-22 failed due to a nearly complete loss
of transfected USSC from the culture plates (data not
shown).
Figure 5 Expression of HDAC4, CDK6, and SMAD1 in native and
osteo-differentiated USSC as well as in response to regulating
miRNAs. Western-blots were scanned and protein expression levels
quantified, normalized against the housekeeping proteins α-tubulin
or ß-actin, and compared to expression in native/untransfected cells
(percent values shown below the blot scans). (A) HDAC4 expression
in native and osteo-differentiated (day 9) USSC 86b, (B) HDAC4
expression in USSC86b in response to transfection of a miR-29b
mimic compared to transfection of a negative control small RNA
and untransfected (native) cells. (C) CDK6 expression in native USSC
86b and USSC 77, on days 7 and 12 post DAG induction. (D) CDK6
expression in USSC 86b in response to transfection with miR-26a/b,
miR-29b and a negative control small RNA as compared to native
cells. (E) SMAD1 expression in native and day 9-osteo-differentiated
cells USSC 86b, (F) SMAD1 expression in response to transfection of
USSC 86b with miR-26a/b as compared to negative control
transfected and native cells.
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and osteo-promoting factors in parallel, the osteo-inhibitory
effects of CDK6 and HDAC4 likely outweigh the osteo-
promoting effects of SMAD1; this finding is further
supported by the unaltered abundance of SMAD1 in miR-
26a/b transfected USSC.
The strongest effect on osteogenic differentiation was
observed by transfecting an equimolar mixture of miR-
26a, miR-26b, and miR-29b mimics. It is likely that miR-26a/b and miR-29b influence a common set of target
genes with each miRNA making additional contributions
through targeting exclusive genes e.g. HDAC4 and
CTNNBIP1, which are regulated by miR-29b but not by
miR-26a/b.
Recently miR-135b was reported to be 100-fold up-
regulated in USSC following DAG-induction [61]. In con-
trast, Li and coworkers reported that miR-135b (and also
miR-133a/b) were downregulated during mouse osteoblast
differentiation after 16 hours [30]. In USSC, miR-133a and
miR-133b as well as miR-135b are only weakly expressed
even in native cells and virtually unchanged during osteo-
genic differentiation (see Additional file 1).
A recent study of miRNA expression signatures assso-
ciated with osteogenic commitment of USSC showed
upregulation of similar miRNAs (miR-26b, miR-30b, let-
7a, let-7f and miR-181a) as determined in our analysis
[62]. However the authors used USSC from a different
source, employed different miRNA expression analysis
methodology (hybridisation array), and focused on other
miRNAs, precluding direct comparison.
Taken together, our results further establish the import-
ance of miRNAs in differentiation processes of USSC. We
clearly demonstrated the combined functional impact of
miR-26a/b and miR-29b, which had individually been
identified as modulators of osteogenic differentiation in
hADSC [31] and mouse osteoblasts [32]. Target gene simi-
larities and differences between these miRNAs imply that
these miRNAs act in a synergistic manner to improve and
accelerate osteogenic differentiation of USSC.
Conclusions
In summary, we detected a subset of miRNAs, notably
miR-26a, miR-26b and miR-29b, which is consistently
upregulated during osteogenic differentiation of USSC.
We experimentally identified specific osteo-inhibitory
proteins as regulatory targets for these miRNAs in re-
porter gene analyses and in direct measurements of target
protein abundance. Functional analyses demonstrated that
miR-26a, miR-26b and miR-29b positively modulate
osteogenic differentiation of USSC, most likely by down-
regulating osteo-inhibitory target proteins. Together with
our previous studies on neuronal lineage differentiation
[38], [39] these findings further support the notion that dif-
ferentiation of the unique somatic stem cell type USSC
follows established biochemical pathways wherein miRNAs
are important regulatory molecules.
Methods
Generation and osteogenic lineage differentiation of
USSC
USSC lines were isolated from human cord blood and
characterized in a designated unit in our institute under
GMP conditions as described in detail in [33] and [63]
Figure 6 Functional impact of miR-26a/b and miR-29b on osteogenic differentiation of USSC. Impact of miR-26a/b and miR-29b on
osteogenic differentiation on (A, scale bars 200μm) USSC SA5/73 at day 7 and (B, scale bars 500μm) on osteogenic differentiation of USSC 86b at
day 7 post induction of DAG-induced differentiation was analyzed. Alizarin-red staining of native uninduced USSC and DAG-induced cells are
shown in comparison to DAG-induced cells transfected with a negative control smallRNA, miRNA mimics miR-26a/b (equimolar batch), miR-29b,
and miR-26a/b/29b (equimolar batch).
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was obtained from each participant.
USSC lines SA5/73 and SA8/25 were induced to osteo-
genic differentiation on addition of DAG (dexamethasone,
ascorbic acid, ß-glycerolphosphate). Cells were incubated
for 7 days and osteogenic differentiation was assessed
using Alizarin-Red staining as described [33]. Calcium re-
lease was measured following incubation of cells in 6M
HCl for 24h at 37°C; calcium content in the supernatant
was analyzed using the Calcium Colorimetric Assay
(BioVision) according to the manufacturer’s instructions
followed by normalization to the protein content of the
sample.miRNA expression analysis
Small and large RNA fractions were isolated from native
and differentiated USSC lines SA5/73 and SA8/25 using
the Ambion mirVana miRNA Isolation kit (Applied
Biosystems, Darmstadt, FRG) according to the manu-
facturer’s instructions; adherent USSC were directly
lysed without cell trypsinization. Total RNA for small
RNA sequencing was prepared using TRIzol reagent
(Invitrogen, FRG).
miRNA expression analyses were performed on small
RNA fractions using the TaqMan miRNA Megaplex array
(pool A, Applied Biosystems, Darmstadt, FRG) [43]
according to the manufacturer’s instructions. Briefly, 10ng
Figure 7 Calcium-release assay from cells used in functional assays described in Figure 5. (A) USSC SA5/73, (B) USSC 86b. Percent mean
values from experimental duplicates are given. In both cell lines, calcium release increased upon transfection with miR-26a/b and miR-29b
followed by DAG-induction, as compared with untransfected/neg. control-transfected cells.
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fied for 12 PCR cycles, with subsequent TaqMan-probe
based array-amplification for 40 additional PCR cycles.
Raw Ct-values were normalized to U6 RNA data and ddCt
as well as 2-(ddCt) data were calculated.
Barcoded small RNA sequencing was used to generate
miRNA expression profiles for four native USSC lines
(SA5/73, SA8/25, SA8/77, SA4/101) and two day 7-osteo
-differentiated USSC lines (SA8/77 and SA4/101); this
method is a modification of an established small RNA
sequencing protocol which involves sequential ligation
of 30 and 50 adapters to small RNAs, followed by cDNAlibrary preparation, Solexa sequencing, and small RNA
annotation [56].
Bioinformatic target gene predictions
Most miRNA targets were predicted using the miRGen
engine (http://www.diana.pcbi.upenn.edu/miRGen.html);
additional targets were identified using miRanda (http://
www.microrna.org/microrna/getGeneForm.do), PicTar
(http://pictar.mdc-berlin.de/), and TargetScan webtools
(http://www.targetscan.org/). Further analyses (gene
ontology) of predicted targets were performed using the
DAVID database (http://david.abcc.ncifcrf.gov/home.jsp).
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predictions
PCR-products of full length or fragments of 30-UTRs as
well as double-stranded oligonucleotides covering the
predicted miRNA binding sites on the target mRNA of
interest were cloned at the 30-end of firefly luciferase
ORF in dual reporter (firefly and renilla luciferases) vec-
tor pmirGLO (GenBank accession FJ376737, Promega
Mannheim, FRG) using restriction enzyme pairs SacI/
XbaI or SalI/XhoI. PCR primers, sense and antisense
oligonucleotides, and 30-UTR- and fragment-lengths are
listed in Additional file 3. To normalize for effects of
endogenous miRNAs on a given 30-UTR, 100ng
pmirGLO and pmirGLO/30-UTR were transfected into
5×104 HEK293T cells using 0.5 μl Lipofectamine 2000
(Invitrogen, Karlsruhe, FRG). Pairwise cotransfections of
100ng empty pmirGLO with the 2.5 pmol miRNA mimic
(Dharmacon, Bonn, FRG) of interest and pmirGLO/30-
UTR with the miRNA mimic of interest were performed
to determine the influence of the given miRNA on the 30-
UTR. Firefly and renilla activities were measured 24h
after transfection using Beetlejuice and Renillajuice
reagents (PJK, Kleinblittersdorf, FRG). All transfection
experiments were performed in at least two independent
biological experiments with quadruple transfections each
and statistical significances were calculated by a student’s
t-test, unpaired.
Real-time PCR analysis
Total RNA was isolated using Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. RNAs were
reverse transcribed using M-MLV reverse transcriptase
(Promega, Mannheim, FRG) and real-time PCRs were
performed using the Maxima SYBR Green/ROX qPCR
Master Mix (Fermentas, St. Leon-Rot, FRG). Primers for
CDK6 [64], CTNNBIP1 [65], SMAD1 [31] and HDAC4
(this work) used in RT-reactions are listed in Additional
file 3. Results were analyzed using Step One Software
v2.1 and statistical significances were calculated by a
student’s t-test, unpaired.
Transfections of USSC for Western blots and functional
analyses
To analyze changes in endogenous protein abundance dur-
ing osteogenesis, USSC were cultivated on 6-well plates
and induced with DAG as described above. Proteins were
isolated at days 0 (native), 7, 9, and 12. To evaluate the im-
pact of miRNAs on endogenous target proteins, USSC were
cultivated on 6-well plates and transfected with 40pmol of
relevant miRNA-mimic/well using Dharmafect1 reagent
according to the manufacturer’s instructions, proteins were
isolated 48h after transfection. Native, osteo-differentiated
and transfected USSC were washed with PBS and lysed
using RIPA-Buffer (Sigma, FRG) supplemented withprotease inhibitor cocktail tablets (Roche, FRG). Up to
50μg of proteins/lane were separated by SDS-PAA electro-
phoresis, blotted onto nitrocellulose membranes (0.45μm),
and membranes were blocked with 3% Milk/PBS, incubated
with primary antibodies (see below) in 3% milk/PBS
followed by incubation with the appropiate secondary anti-
body (see below) in 3% milk/PBS/0,15% Tween-20.
Membranes were washed in PBS-T/0.1% Tween-20, dried,
and scanned with the LI-COR Odyssey Infrared Imager
(LI-COR Biosystems). Visible false-color signals were quan-
tified using Odyssey 2.1 software (LI-COR Biosystems) and
normalized against signals from quantified housekeeping
proteins α-Tubulin or ß-Actin. The following antibodies
were used in this study: CDK6, sc-177; HDAC4, sc-11418;
SMAD1, sc-7965 (all Santa Cruz Biotechnology), α-Tubu-
lin, B-5-1-2 (Sigma Aldrich); ß-Actin, ab34731 (abcam);
IRDye 680LT α-mouse and IRDye 800CW α-rabbit (both:
LI-COR Biosystems).
For functional analyses, USSC were cultivated on 24-well
plates and transfected with 10pmol miRNA-mimic/well
using Dharmafect1 reagent according to the manu-
facturer’s instructions. Transfected cells were induced
to osteogenic differentiation 24 h post transfection as
described above. Differentiation was analyzed at day 7 by
alizarin-red stainig and calcium released as described
above.
Ethics statement
Work with USSC was approved by the Ethics Commit-
tee of the Medical Faculty, University Düsseldorf, study
numbers 3436 and 2975.
Additional files
Additional file 1: Comprehensive miRNA expression data from
native (d0) USSC SA5/73 and SA8/25 and osteo-differentiated (day
7) SA5/73 and SA8/25. This Excel file contains three separate sheets,
“USSC SA573”, “USSC SA825”, and “Deep Sequencing”. In the first two,
raw Ct, U6-RNA normalized dCt, ddCt, and 2-ddCt values (corresponding
to fold changes of miRNA expression in day 7 osteo vs. native cells, in
grey columns) are given for each miRNA analyzed. The sheet “deep
sequencing” indicates results from deep-sequencing derived expression
analysis of miR-26a and miR-26b in native USSC SA5/73, SA8/25, SA8/77,
and SA4/101 and osteo-differentiated USSC SA8/77 and SA4/101. Total
sequence reads for the miRNA indicated as well as frequency of specific
sequence reads among all sequence reads are given.
Additional file 2: Experimental validation of miRNA target gene
predictions. Detailed data of validations of CTNNBIP1 (A), DUSP2 (B),
HDAC4-1 (C), HDAC4-O1 and HDAC4-O2 (D), SMAD1 (E), SMAD6 (F),
TGFB3 (G), and TOB1 (H) are given. The bar above the graphs depict the
respective 30-UTRs, with the blue part representing the analyzed
fragment, including putative miRNA binding sites. For further description
see Figure 2.
Additional file 3: Primers and oligonucleotides. This Excel file
summarizes primers and sense- and antisense-oligonucleotides used for
30-UTR cloning and qRT-PCR analysis. Sheet “30UTR cloning”: Primers for
generation of PCR products from 30-UTRs, corresponding NCBI accession
numbers, and sense- and antisense-oligonucleotides used for
experimental target validation of predicted target proteins. Restriction
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http://www.biomedcentral.com/1471-2164/14/111sites used for cloning are given in bold as well as sticky and recessed
ends synthesized into oligonucleotides. “Ⓟ” denotes the phosphate
group added to the 50-end of oligonucleotides. Mutations in
oligonucleotide sequences corresponding to the seed of microRNAs are
given in red. Sheet “qRT-PCR”: Forward and reverse primers used for RT-
reaction.
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